TrialPath
Recruiting

Randomized Study to Evaluate the Effect of Obicetrapib in Participants With Preclinical Alzheimer's Disease

NCT07794670 · NewAmsterdam Pharma
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
A Phase 2b, Randomized, Double Blind, Placebo Controlled, Parallel Group Trial to Assess the Efficacy and Safety of Obicetrapib in Participants With Preclinical Alzheimer's Disease (SPINOZA Trial)
About this study
A study evaluating Obicetrapib in adults potentially at risk for Preclinical Alzheimer's Disease
Eligibility criteria
Inclusion Criteria: * participants with preclinical AD Exclusion Criteria: * APOE genotype not meeting protocol-defined eligibility criteria
Study design
Enrollment target: 400 participants
Allocation: randomized
Masking: triple
Age groups: adult, older_adult
Timeline
Starts: 2026-09
Estimated completion: 2029-05
Last updated: 2026-09-28
Interventions
Drug: Obicetrapib 10 mgDrug: Matching placebo tablets
Primary outcomes
  • • Change from Baseline to Week 52 in ptau 217 (Baseline, Week 52)
Sponsor
NewAmsterdam Pharma · industry
All locations (1)
K2 Medical ResearchRecruiting
Nashville, Tennessee, United States
Randomized Study to Evaluate the Effect of Obicetrapib in Participants With Preclinical Alzheimer's Disease · TrialPath